The MarketWatch News Department was not involved in the creation of this content. Cure HHT plays pivotal role in the NIH-sponsored PATH Trial becoming the first successful, large-scale randomized ...
A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
Wednesday, September 18, 2024, CLEVELAND: A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare ...
Series B funds will enable clinical development of ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary ...
MANHASSET, N.Y.--(BUSINESS WIRE)--A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia (HHT) – a rare genetic bleeding condition ...
Strategically developed to promote the care team’s awareness of HHT and galvanize optimization of HHT-associated IDA management, this series of Ace the Case sessions will highlight key teaching points ...
Area of focus: translational research in vascular biology, including studies on endothelial cells, platelets and other blood cells. When a patient presented with challenging nosebleeds and severe ...
Please provide your email address to receive an email when new articles are posted on . Strategically developed to promote the care team’s awareness of HHT and galvanize optimization of HHT-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results